YTX treatment decreases tumour development in the B16F10 melanoma mouse model. by Araceli Tobío (3545306)

A decrease in CD44+ cells in response to hypoxia. by Daniel V. Brown (3797809)

FHL2 silencing decreases osteosarcoma cell growth. by Julia Brun (286504)

Schematic representation of the molecular mechanism by which iRF decreases the aggressiveness of B16F10 cells. by Daisy Machado (288559)

Subjects:

S16 Fig - by Jordan K. Abbott (8934239)

SAS decreases cellular resistance to H₂O₂. by Masaki Nagane (5094860)

Human uterine PPP1R16A and PPP1R16B mRNA expression is decreased during pregnancy and in labor. by Jon Lartey (320918)

Adoptive transfer of mature NK cells decreases the incidence of BA and improves survival, and the level of VP4 in cholangiocytes and the incidence of BA are decreased as the age of... by Yinrong Qiu (345978)

Suppression of the growth defects in flippase mutants by decreased synthesis of PI. by Kanako Yamagami (703555)

Exposure of HOB to chemotherapeutic agents or rTGF-β1 decreased the expression of CXCL-12 and diminished support of pro-B cell chemotaxis. by Stephanie L. Rellick (182765)

IκBαM.1-Infected Mice Have Decreased Latency in Lung B Cells 16 dpi after Intranasal Infection by Laurie T Krug (68237)

Knockdown of xCT decreases cellular resistance to H₂O₂. by Masaki Nagane (5094860)

Glucose inhibition decreases IL-1β levels and tumor progression in the B16F10 mouse model. by Yunseo Woo (6157307)

Effect of melatonin (50 μM) on the TGF-β1 (10 ng/mL, 72 h)-mediated TGF-β1/Smad pathway and EMT in HBdSMCs. by Yang Zhang (30734)

2‑Aminobenzoxazole Derivatives as Potent Inhibitors of the Sphingosine-1-Phosphate Transporter Spinster Homolog 2 (Spns2) by Ariel L. Burgio (15069256)

Subjects:

Binding of compound 16 with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

General procedure for the synthesis of the target compounds 16–20. by Ahmed A. Gaber (13302308)

Subjects:

Decreased pre-miR16-1 and Mature miR16-1 in NZB. by Siddha Kasar (2557828)

Systemic inhibition of CSF-1R decreases B16F10-induced accumulation of blood monocyte subsets. by Marjolein Sluijter (613087)

Subjects:

Brivanib decreases viability of PDGF-BB treated LX-2 cells. by Ikuo Nakamura (548298)

“…Cells showed a brivanib dose-dependent decrease in viability, with half maximal inhibitory concentration (IC₅₀) of 16.98 µM (95% CI 13.95 µM–20.67 µM). …”